Professor Palti founded Novocure to provide patients with a new cancer treatment based on his hypothesis, since proven, that alternating electric fields, when applied at specific frequencies, can disrupt cancer cell division. This innovative treatment, Tumor Treating Fields, is a completely different approach to cancer therapy.
Palti’s initial research from his basement laboratory evolved to become Novocure – an international oncology company with more than 1,000 employees and operations in North America, Europe, the Middle East and Asia.
Our company began with a patient-forward approach that continues to drive our mission today. With more than 20 years of research and many significant milestones, we believe we are only beginning.
